127 related articles for article (PubMed ID: 30920860)
1. Associations of
Shen X; Zhao Y; Chen X; Sun H; Liu M; Zhang W; Jiang F; Li P
Future Oncol; 2019 Jun; 15(16):1873-1894. PubMed ID: 30920860
[No Abstract] [Full Text] [Related]
2. PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene.
Polom K; Marrelli D; Roviello G; Pascale V; Voglino C; Vindigni C; Generali D; Roviello F
Adv Clin Exp Med; 2018 Jul; 27(7):963-969. PubMed ID: 29905413
[TBL] [Abstract][Full Text] [Related]
3. Exon 9 Mutation of
Seo AN; Kang BW; Bae HI; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Jeon SW; Kang H; Kim JG
Anticancer Res; 2019 Apr; 39(4):2145-2154. PubMed ID: 30952761
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
Böger C; Krüger S; Behrens HM; Bock S; Haag J; Kalthoff H; Röcken C
Ann Oncol; 2017 May; 28(5):1005-1014. PubMed ID: 28453696
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
Harada K; Baba Y; Shigaki H; Ishimoto T; Miyake K; Kosumi K; Tokunaga R; Izumi D; Ohuchi M; Nakamura K; Kiyozumi Y; Kurashige J; Iwatsuki M; Miyamoto Y; Sakamoto Y; Yoshida N; Watanabe M; Baba H
BMC Cancer; 2016 Jul; 16():400. PubMed ID: 27388016
[TBL] [Abstract][Full Text] [Related]
6. Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer.
Yu Y; Xie Z; Zhao M; Lian X
BMC Cancer; 2021 Apr; 21(1):368. PubMed ID: 33827485
[TBL] [Abstract][Full Text] [Related]
7. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
8. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
Li X; Pasche B; Zhang W; Chen K
JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
[TBL] [Abstract][Full Text] [Related]
9. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract][Full Text] [Related]
10. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.
Shi J; Yao D; Liu W; Wang N; Lv H; Zhang G; Ji M; Xu L; He N; Shi B; Hou P
BMC Cancer; 2012 Feb; 12():50. PubMed ID: 22292935
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
Mei ZB; Duan CY; Li CB; Cui L; Ogino S
Ann Oncol; 2016 Oct; 27(10):1836-48. PubMed ID: 27436848
[TBL] [Abstract][Full Text] [Related]
12. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
13. Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.
Ito C; Nishizuka SS; Ishida K; Uesugi N; Sugai T; Tamura G; Koeda K; Sasaki A
J Surg Res; 2017 May; 212():195-204. PubMed ID: 28550907
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Kim HS; Lee SE; Bae YS; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Lee YC; Kim HR; Shim YM; Jewell SS; Kim H; Choi YL; Cho BC
Oncotarget; 2016 May; 7(21):30691-701. PubMed ID: 27095573
[TBL] [Abstract][Full Text] [Related]
16.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
17. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
